Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
Part of Cancer clinical trials.
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that has spread or cannot be removed, and it has a specific genetic change called KRAS G12C.
- You have already tried at least one standard cancer treatment (like chemo or immunotherapy) and it stopped working, or you couldn't take it.
- If you have had a G12C inhibitor before, it must have stopped working or caused bad side effects.
- You have a sample of your tumor (from a biopsy or surgery) that can be tested, or you are willing to have a new biopsy if it's safe.
- You are in generally good health (able to do daily activities) and expected to live at least 12 more weeks.
- You must not have active brain tumors that are untreated or causing symptoms, or a history of severe lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
Hear when a new Advanced Solid Tumors Harboring KRAS G12C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.